US Medicare issues updated rules for second round of drug negotiations
By Ahmed Aboulenein
WASHINGTON, Oct 2 (Reuters) -The U.S. government will provide more time for negotiations and more chances for drugmakers to submit counter offers during the second round of talks over price cuts for its Medicare program, it said on Wednesday.
WHY IT'S IMPORTANT
The Centers for Medicare and Medicaid Services (CMS), which oversees Medicare, the government health insurance program for millions of Americans age 65 and older and the disabled, by Feb. 1 will select the costliest prescription medications to negotiate on, with prices coming into effect in 2027.
The guidance is being closely watched by pharmaceutical manufacturers who make the 15 drugs likely to get picked for negotiations.
CMS said changes to the process, which came after feedback from patients and drugmakers, include meeting with companies earlier in the process and allowing more opportunities for counter offers.
The agency will now meet with drugmakers before making its initial offer, and will hold one of the three allotted negotiation meetings before the deadline for the first counter offer. If a company chooses to counter the government's offer, it will have two further meetings to negotiate.
KEY QUOTES
"What we plan to do is have meetings with manufacturers before CMS actually sends an initial offer. But then once we have done an initial offer, we will have a first optional negotiation meeting with the manufacturer earlier than we did this past year," a CMS official told reporters on a press call.
"That will provide us with an opportunity to have a dialogue about the initial offer that CMS has sent, and potentially some early thinking from the manufacturer themselves around how they might do a counteroffer."
CONTEXT
CMS announced prices for ten drugs in August in its first round of cuts following a year of talks. The prices are set to take effect in January 2026 and will save older Americans $1.5 billion in out of pocket costs, according to the agency.
Next year's talks will take place in a shorter timeframe, with a final decision on prices due by Nov. 30, 2025.
Reporting by Ahmed Aboulenein; Editing by Sonali Paul
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
